Hydralazine was the most common drug for others to be evaluated against .
Diazoxide , given as 75 mg bolus injections , appears to be associated with maternal hypotension requiring treatment , and ketanserin is less effective than hydralazine at reducing blood pressure .
There is no other clear evidence that any one of the other antihypertensive agents is better than another for women with severe hypertension during pregnancy .
Exceptions are diazoxide and ketanserin , which are probably not good choices
BACKGROUND Very high blood pressure during pregnancy poses a serious threat to women and their babies .
The use of drugs to lower blood pressure will reduce this risk for the women , and possibly also for the baby .
OBJECTIVES The objective of this review was to compare different antihypertensive drugs used for treatment of severe hypertension during pregnancy .
Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. BI51.017 Study Group.
A double-blind , r and omized , placebo-controlled trial was conducted to evaluate whether treatment with Antithrombin ( AT ) concentrates improved the clinical and perinatal outcome in patients with severe preeclampsia . Severe preeclamptic patients ( 24 to 35 weeks of gestation . Gestosis Index ( GI ) > or = 6 points ) were r and omized into two groups : 66 received AT and 67 received placebo . There were no statistical differences in the clinical profiles of the two groups . Study drugs were given intravenously once daily for 7 consecutive days . Maternal symptoms were evaluated from the difference of GI between before and after treatment , and fetal findings were evaluated from the changes of the biophysical profile score and the estimated fetal weight gain . Improvement was significantly greater in the AT group for both the GI ( p = 0.020 ) and the estimated fetal weight gain ( p = 0.029 ) . The improvement of coagulation parameters was also evaluated . The D-dimer levels increased significantly in the placebo group ( p = 0.026 ) , but did not change in the AT group . Gestation was significantly prolonged ( p = 0.007 ) , and the number of low-birth weight infants was significantly smaller ( p = 0.011 ) in the AT group . No adverse events related to AT were observed . It is revealed that AT concentrate therapy for preeclampsia is effective and safe , leading to an improved perinatal outcome
Hydralazine was the most common drug for others to be evaluated against .
Diazoxide , given as 75 mg bolus injections , appears to be associated with maternal hypotension requiring treatment , and ketanserin is less effective than hydralazine at reducing blood pressure .
There is no other clear evidence that any one of the other antihypertensive agents is better than another for women with severe hypertension during pregnancy .
Exceptions are diazoxide and ketanserin , which are probably not good choices
BACKGROUND Very high blood pressure during pregnancy poses a serious threat to women and their babies .
The use of drugs to lower blood pressure will reduce this risk for the women , and possibly also for the baby .
OBJECTIVES The objective of this review was to compare different antihypertensive drugs used for treatment of severe hypertension during pregnancy .